Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension

Haruhito Adam Uchida, Yoshio Nakamura, Masanobu Kaihara, Taro Sugimoto, Hisanori Norii, Motofumi Sasaki, Hajime Sato, Hirofumi Makino

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The current guideline-recommended blood pressure values are difficult to maintain in general practice, partly due to the lack of ideal anti-hypertensive agents. Since morning hypertension has a high correlation with cardiovascular events, expectations that telmisartan, a long-acting angiotensin-II type-1 receptor blocker (ARB), can improve cardiovascular mortality are high. In this study, the efficiency of telmisartan in reducing morning hypertension and pulse wave velocity (PWV) as a practical surrogate endpoint was investigated. Seventeen unsupervised and 7 untreated hypertensive patients were prescribed telmisartan 40 mg/day for 3 months. Medication already prescribed upon enrollment in this study was continued, with the exception of ARBs (all of which turned out to be losartan 50 mg/day), which were discontinued and replaced with telmisartan. Morning home blood pressure (MHBP), office blood pressure (OBP), and brachial-ankle PWV (baPWV) were investigated in a prospective fashion. A stratified analysis was performed regarding previous use (group L) or non-use (group N) of losartan. Over a 3-month period, telmisartan was found to significantly reduce both OBP (from 153±13/85±9 to 141±17/80±7 mmHg (p

Original languageEnglish
Pages (from-to)545-550
Number of pages6
JournalHypertension Research
Volume27
Issue number8
DOIs
Publication statusPublished - Aug 2004

Fingerprint

Pulse Wave Analysis
Blood Pressure
Hypertension
Losartan
Angiotensin II Type 1 Receptor Blockers
Ankle
General Practice
Antihypertensive Agents
Arm
Biomarkers
telmisartan
Guidelines
Mortality

Keywords

  • Angiotensin-II type-1 receptor blocker
  • Ankle-brachial pressure index
  • Arterial wall stiffness
  • Losartan
  • Uric acid

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. / Uchida, Haruhito Adam; Nakamura, Yoshio; Kaihara, Masanobu; Sugimoto, Taro; Norii, Hisanori; Sasaki, Motofumi; Sato, Hajime; Makino, Hirofumi.

In: Hypertension Research, Vol. 27, No. 8, 08.2004, p. 545-550.

Research output: Contribution to journalArticle

Uchida, Haruhito Adam ; Nakamura, Yoshio ; Kaihara, Masanobu ; Sugimoto, Taro ; Norii, Hisanori ; Sasaki, Motofumi ; Sato, Hajime ; Makino, Hirofumi. / Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. In: Hypertension Research. 2004 ; Vol. 27, No. 8. pp. 545-550.
@article{014dc3e39ae24f289b2d0ec691048ae3,
title = "Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension",
abstract = "The current guideline-recommended blood pressure values are difficult to maintain in general practice, partly due to the lack of ideal anti-hypertensive agents. Since morning hypertension has a high correlation with cardiovascular events, expectations that telmisartan, a long-acting angiotensin-II type-1 receptor blocker (ARB), can improve cardiovascular mortality are high. In this study, the efficiency of telmisartan in reducing morning hypertension and pulse wave velocity (PWV) as a practical surrogate endpoint was investigated. Seventeen unsupervised and 7 untreated hypertensive patients were prescribed telmisartan 40 mg/day for 3 months. Medication already prescribed upon enrollment in this study was continued, with the exception of ARBs (all of which turned out to be losartan 50 mg/day), which were discontinued and replaced with telmisartan. Morning home blood pressure (MHBP), office blood pressure (OBP), and brachial-ankle PWV (baPWV) were investigated in a prospective fashion. A stratified analysis was performed regarding previous use (group L) or non-use (group N) of losartan. Over a 3-month period, telmisartan was found to significantly reduce both OBP (from 153±13/85±9 to 141±17/80±7 mmHg (p",
keywords = "Angiotensin-II type-1 receptor blocker, Ankle-brachial pressure index, Arterial wall stiffness, Losartan, Uric acid",
author = "Uchida, {Haruhito Adam} and Yoshio Nakamura and Masanobu Kaihara and Taro Sugimoto and Hisanori Norii and Motofumi Sasaki and Hajime Sato and Hirofumi Makino",
year = "2004",
month = "8",
doi = "10.1291/hypres.27.545",
language = "English",
volume = "27",
pages = "545--550",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension

AU - Uchida, Haruhito Adam

AU - Nakamura, Yoshio

AU - Kaihara, Masanobu

AU - Sugimoto, Taro

AU - Norii, Hisanori

AU - Sasaki, Motofumi

AU - Sato, Hajime

AU - Makino, Hirofumi

PY - 2004/8

Y1 - 2004/8

N2 - The current guideline-recommended blood pressure values are difficult to maintain in general practice, partly due to the lack of ideal anti-hypertensive agents. Since morning hypertension has a high correlation with cardiovascular events, expectations that telmisartan, a long-acting angiotensin-II type-1 receptor blocker (ARB), can improve cardiovascular mortality are high. In this study, the efficiency of telmisartan in reducing morning hypertension and pulse wave velocity (PWV) as a practical surrogate endpoint was investigated. Seventeen unsupervised and 7 untreated hypertensive patients were prescribed telmisartan 40 mg/day for 3 months. Medication already prescribed upon enrollment in this study was continued, with the exception of ARBs (all of which turned out to be losartan 50 mg/day), which were discontinued and replaced with telmisartan. Morning home blood pressure (MHBP), office blood pressure (OBP), and brachial-ankle PWV (baPWV) were investigated in a prospective fashion. A stratified analysis was performed regarding previous use (group L) or non-use (group N) of losartan. Over a 3-month period, telmisartan was found to significantly reduce both OBP (from 153±13/85±9 to 141±17/80±7 mmHg (p

AB - The current guideline-recommended blood pressure values are difficult to maintain in general practice, partly due to the lack of ideal anti-hypertensive agents. Since morning hypertension has a high correlation with cardiovascular events, expectations that telmisartan, a long-acting angiotensin-II type-1 receptor blocker (ARB), can improve cardiovascular mortality are high. In this study, the efficiency of telmisartan in reducing morning hypertension and pulse wave velocity (PWV) as a practical surrogate endpoint was investigated. Seventeen unsupervised and 7 untreated hypertensive patients were prescribed telmisartan 40 mg/day for 3 months. Medication already prescribed upon enrollment in this study was continued, with the exception of ARBs (all of which turned out to be losartan 50 mg/day), which were discontinued and replaced with telmisartan. Morning home blood pressure (MHBP), office blood pressure (OBP), and brachial-ankle PWV (baPWV) were investigated in a prospective fashion. A stratified analysis was performed regarding previous use (group L) or non-use (group N) of losartan. Over a 3-month period, telmisartan was found to significantly reduce both OBP (from 153±13/85±9 to 141±17/80±7 mmHg (p

KW - Angiotensin-II type-1 receptor blocker

KW - Ankle-brachial pressure index

KW - Arterial wall stiffness

KW - Losartan

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=5044235079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044235079&partnerID=8YFLogxK

U2 - 10.1291/hypres.27.545

DO - 10.1291/hypres.27.545

M3 - Article

C2 - 15492473

AN - SCOPUS:5044235079

VL - 27

SP - 545

EP - 550

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 8

ER -